About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 will deliver top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.
| • Download the initiation report on NOXXON by Aurgalys |
| ➥ See latest updates from Aurgalys here |
Press ReleaseBerlin, Germany
2018, November 21 8:00 a.m. NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer 2018, November 16 8:00 a.m. NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC 2018, October 26 8:00 a.m. NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference |
EventsAram Mangasarian Aram Mangasarian |